Effect of Smoking and E-cigarette(Vape) on Liver Enzymes and Lipid Profile in  Iraqi People with Dyslipidemia and Liver Disease

Abduqader W.  Rasheid

Abduqader W. Rasheid Ministry of Education/ The Open Educational College, Salah eldin, Iraq.

Keywords: E-cigarette, Vape Smoking, Liver Disease, Liver Toxicity, Biochemistry Marker, Dyslipidemia

Abstract

There is an increased trend of e-cigarette but the toxic effects of e-cigarette metabolites are not widely studied especially in liver disease. Study showed evaluate the prevalence and patterns of recent e-cigarette use in a nationally representative sample of Iraqi adults are association with liver disease and revealed a significant association between e-cigarette use, dyslipidemia, in Iraqi adults and adolescents. 88% of e-cigarette users with comorbid liver disease and dyslipidemia exhibited elevated liver enzyme levels, underscoring a potential pathophysiological interplay between lipid dysregulation and hepatotoxicity. Among hepatic biomarkers, serum gamma-glutamyl transferase (GGT) demonstrated the strongest independent correlation with lipid profile derangements, positioning GGT and hyperlipidemia as critical biomarkers for monitoring lipid-induced hepatic injury and its clinical progression. liver disease exhibited lower e-cigarette use prevalence compared to non smoker (6.4%) smokers (7.2%), multivariate logistic regression identified e-cigarette use (OR: 1.06; 95% CI: 1.05–1.06, *p*<0.0001) and non smoker (OR: 1.50; 95% CI: 1.50–1.51, p<0.0001) as independent risk factors for liver disease history. Paradoxically, despite lower absolute e-cigarette use frequency in liver disease cohorts, the elevated odds ratios highlight a disproportionate risk burden in dyslipidemic individuals. Additionally, traditional cigarette smokers showed significantly higher hemoglobin (Hb) levels than e-cigarette users, implying divergent systemic effects of smoking types.

Downloads

Download data is not yet available.

References

S. K. Asrani, H. Devarbhavi, and J. Eaton, “Burden of liver diseases in the world,” J. Hepatol., vol. 70, pp. 151–171, 2019.

C. Griffin, U. Agbim, and A. Ramani, “Underestimation of cirrhosis-related mortality in the Medicare-eligible population, 1999-2019,” Clin. Gastroenterol. Hepatol., vol. 21, pp. 223–225, 2021.

GBDC Collaborators, “The global, regional, and national burden of cirrhosis by cause in 195 countries and territories, 1990-2019: A systematic analysis for the Global Burden of Disease Study 2019,” Lancet Gastroenterol. Hepatol., vol. 5, pp. 244–267, 2020.

P. Jepsen and Z. M. Younossi, “The global burden of cirrhosis: A review of disability-adjusted life-years lost and unmet needs,” J. Hepatol., vol. 75, pp. S3–S12, 2021.

H. Devarbhavi et al., “Global burden of liver disease: 2023 update,” J. Hepatol., vol. 79, no. 2, pp. 516–537, Aug. 2023.

C. Ma, A. S. Qian, and N. H. Nguyen, “Trends in the economic burden of chronic liver diseases and cirrhosis in the United States: 1998-2019,” Am. J. Gastroenterol., vol. 116, pp. 2059–2068, 2021.

J. Eda et al., “Nicotine induces fibrogenic changes in human liver via nicotinic acetylcholine receptors expressed on hepatic stellate cells,” Biochem. Biophys. Res. Commun., vol. 417, no. 1, pp. 17–22, 2022.

Y. Arnson, Y. Seinfeld, and H. Amidala, “Effects of tobacco smoke on immunity, inflammation and autoimmunity,” J. Autoimmune, vol. 34, no. 3, pp. J257–J266, 2015.

R. E. Fleming and P. Polka, “Iron overload in human disease,” N. Engl. J. Med., vol. 366, no. 4, pp. 347–358, 2022.

K. M. Hassan et al., “E-cigarettes and Western diet: Important metabolic risk factors for hepatic diseases,” Hepatology, vol. 69, no. 6, pp. 2441–2455, 2019.

M. Xiong et al., “Impacts of cigarette smoking on liver fibrosis and its regression under therapy in male patients with chronic hepatitis B,” Liver Int., vol. 39, no. 8, pp. 1428–1436, 2019.

“Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies,” J. Hepatol., vol. 69, pp. 718–735, 2018.

V. M. Mehra et al., “The association between alcohol, marijuana, illegal drug use and current use of E-cigarette among youth and young adults in Canada: Results from Canadian Tobacco, Alcohol and Drugs Survey 2017,” BMC Public Health, vol. 19, no. 1, p. 1208, 2019.

M. A. Khaleefah, H. J. Al-Badri, and N. A. Mousa, “Hypertension control among adult Iraqis,” J. Fac. Med. Baghdad, vol. 64, no. 3, pp. 145–152, Oct. 2022.

K. T. Mills, A. Stefanescu, and J. He, “The global epidemiology of hypertension,” Nat. Rev. Nephrol., vol. 16, pp. 222–238, 2020.

R. K. Nasif and S. R. Ibraheem, “The relationship between liver enzymes level and obesity in a sample of Iraqi women,” Iraqi J. Biotechnol., vol. 21, no. 2, pp. 663–667, 2022.

W. Egner, “The use of laboratory tests in the diagnosis of SLE,” J. Clin. Pathol., vol. 64, no. 7, pp. 427–431, 2020.

K. K. Farmanfarma et al., “Prevalence of type 2 diabetes in Middle–East: Systematic review & meta-analysis,” Prim. Care Diabetes, vol. 14, pp. 297–304, 2020.

O. H. Qader and M. Saka, “Prevalence of risk factors of acute coronary syndrome in Erbil Cardiac Center: Comparing ST-elevation with non-ST-elevation acute coronary syndrome,” Adv. Med. J., vol. 9, no. 1, pp. 144–152, 2024.

A. Abera, A. Worede, and A. T. Hirigo, “Dyslipidemia and associated factors among adult cardiac patients: A hospital-based comparative cross-sectional study,” Eur. J. Med. Res., vol. 29, p. 237, 2024.

N. Murad et al., “Modifiable risk factors for cardiovascular disease in Iraqi Kurdistan population: A large epidemiological study,” Healthc. Low-Resour. Settings, vol. 12, no. 2, 2023.

W. A. Mula-Abed and S. K. Chilmeran, “Prevalence of dyslipidemia in the Iraqi adult population,” Saudi Med. J., vol. 28, no. 12, pp. 1868–1874, Dec. 2007.

D. A. F. Al-Koofee, J. M. Ismail, and A. A. Algenab, “Lipid profile survey in adults in An-Najaf/Iraq: A cross-sectional study,” J. Phys.: Conf. Ser., vol. 1294, no. 5, p. 052018, 2019.

S. Abdul Wahab ALShaban et al., “Study the effect of dyslipidemia in Iraqi diabetes patients with both gender,” Hist. Med., vol. 9, no. 2, 2023.

H. Baqi, T. Abdullah, D. Ghafor, and S. Karim, “Establishment of lipid profile reference intervals in a sample population of Halabja City, Kurdistan Region of Iraq,” Iraqi J. Sci., pp. 2855–2861, 2021.

T. Alhilfi, R. Lafta, and G. Burnham, “Health services in Iraq,” Lancet, vol. 381, pp. 939–948, 2022.

S. Greco et al., “Dyslipidemia, cholangitis and fatty liver disease: The close underexplored relationship: A narrative review,” J. Clin. Med., vol. 13, p. 2714, 2024.

P. Patel et al., “Association of nonalcoholic fatty liver disease with acute cholangitis: A nationwide propensity-matched analysis from the United States,” Bayl. Univ. Med. Cent. Proc., vol. 36, pp. 600–607, 2023.

A. Mellemkjær et al., “Management of cardiovascular risk in patients with metabolic dysfunction-associated steatotic liver disease,” Eur. J. Intern. Med., vol. 122, pp. 28–34, 2024.

L. J. Souza et al., “Prevalence of dyslipidemia and risk factors in Campos dos Goytacazes, in the Brazilian state of Rio de Janeiro,” Arq. Bras. Cardiol., vol. 81, pp. 257–264, 2003.

J. Arauz, E. Ramos-Tovar, and P. Muriel, “Redox state and methods to evaluate oxidative stress in liver damage: From bench to bedside,” Ann. Hepatol., vol. 15, pp. 160–173, 2016.

R. C. Chakinala et al., “Association of smoking and e-cigarette in chronic liver disease: An NHANES study,” Gastroenterology Res., vol. 15, no. 3, pp. 113–119, Jun. 2022.

A. F. Harlow, A. Stokes, and D. R. Brooks, “Socioeconomic and racial/ethnic differences in e-cigarette uptake among cigarette smokers,” Nicotine Tob. Res., vol. 21, no. 10, pp. 1385–1393, 2019.

F. Y. Enc et al., “The interaction between current smoking and hemoglobin on the risk of advanced fibrosis in NAFLD patients,” Eur. J. Gastroenterol. Hepatol., vol. 32, no. 5, pp. 596–599, 2020.